Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2020 Oct 21

PMID 33081166

Citations 6

Authors

Ayman Abouzayed

Hanna Tano

Abel Nagy

Sara S Rinne

Fadya Wadeea

Sharmishtaa Kumar

Kristina Westerlund

Vladimir Tolmachev

Amelie Eriksson Karlstrom

Anna Orlova

Affiliations

Soon will be listed here.

Abstract

The targeting of gastrin-releasing peptide receptors (GRPR) was recently proposed for targeted therapy, e.g., radiotherapy. Multiple and frequent injections of peptide-based therapeutic agents would be required due to rapid blood clearance. By conjugation of the GRPR antagonist RM26 (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH) to an ABD (albumin-binding domain), we aimed to extend the blood circulation of peptides. The synthesized conjugate DOTA-ABD-RM26 was labelled with indium-111 and evaluated in vitro and in vivo. The labelled conjugate was stable in PBS and retained specificity and its antagonistic function against GRPR. The half-maximal inhibitory concentration (IC) of In-DOTA-ABD-RM26 in the presence of human serum albumin was 49 ± 5 nM. [In]In-DOTA-ABD-RM26 had a significantly longer residence time in blood and in tumors (without a significant decrease of up to 144 h pi) than the parental RM26 peptide. We conclude that the ABD-RM26 conjugate can be used for GRPR-targeted therapy and delivery of cytotoxic drugs. However, the undesirable elevated activity uptake in kidneys abolishes its use for radionuclide therapy. This proof-of-principle study justified further optimization of the molecular design of the ABD-RM26 conjugate.

Citing Articles

GRPR Drives Metastasis via CRABP2 and FNDC4 Pathways in Lung Adenocarcinoma.

Kim D, Choi E, Ahn H, Kim Y Cells. 2025; 13(24.

PMID: 39768218 PMC: 11674891. DOI: 10.3390/cells13242128.

Evaluation of ABD-Linked RM26 Conjugates for GRPR-Targeted Drug Delivery.

Nagy A, Abouzayed A, Kanellopoulos P, Landmark F, Bezverkhniaia E, Tolmachev V ACS Omega. 2024; 9(34):36122-36133.

PMID: 39220525 PMC: 11359615. DOI: 10.1021/acsomega.4c00489.

Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology.

Kanellopoulos P, Mattsson A, Abouzayed A, Obeid K, Nock B, Tolmachev V EJNMMI Radiopharm Chem. 2024; 9(1):13.

PMID: 38366299 PMC: 10873254. DOI: 10.1186/s41181-024-00242-6.

The Application of Radiolabeled Targeted Molecular Probes for the Diagnosis and Treatment of Prostate Cancer.

Cheng L, Yang T, Zhang J, Gao F, Yang L, Tao W Korean J Radiol. 2023; 24(6):574-589.

PMID: 37271211 PMC: 10248352. DOI: 10.3348/kjr.2022.1002.

Targeting the Gastrin-Releasing Peptide Receptor (GRP-R) in Cancer Therapy: Development of Bombesin-Based Peptide-Drug Conjugates.

Gomena J, Vari B, Olah-Szabo R, Biri-Kovacs B, Bosze S, Borbely A Int J Mol Sci. 2023; 24(4).

PMID: 36834815 PMC: 9967152. DOI: 10.3390/ijms24043400.

References

Mervic M, Moody T, Komoriya A . A structure function study of C-terminal extensions of bombesin. Peptides. 1991; 12(5):1149-51. DOI: 10.1016/0196-9781(91)90072-w. View

Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K . Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007; 67(6):2773-82. DOI: 10.1158/0008-5472.CAN-06-1630. View

Korner M, Waser B, Rehmann R, Reubi J . Early over-expression of GRP receptors in prostatic carcinogenesis. Prostate. 2013; 74(2):217-24. DOI: 10.1002/pros.22743. View

Casanueva F, Perez F, Casabiell X, Camina J, Cai R, Schally A . Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines. Proc Natl Acad Sci U S A. 1996; 93(4):1406-11. PMC: 39951. DOI: 10.1073/pnas.93.4.1406. View

Cavatorta P, Farruggia G, Masotti L, Sartor G, Szabo A . Conformational flexibility of the hormonal peptide bombesin and its interaction with lipids. Biochem Biophys Res Commun. 1986; 141(1):99-105. DOI: 10.1016/s0006-291x(86)80340-0. View

Mitran B, Tolmachev V, Orlova A . Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer - Influence of Labeling Chemistry on Targeting Properties. Curr Med Chem. 2020; 27(41):7090-7111. DOI: 10.2174/0929867327666200312114902. View

Mitran B, Varasteh Z, Selvaraju R, Lindeberg G, Sorensen J, Larhed M . Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. Int J Oncol. 2016; 48(5):2124-34. DOI: 10.3892/ijo.2016.3429. View

Scholtz J, Qian H, York E, Stewart J, Baldwin R . Parameters of helix-coil transition theory for alanine-based peptides of varying chain lengths in water. Biopolymers. 1991; 31(13):1463-70. DOI: 10.1002/bip.360311304. View

Dalm S, Bakker I, de Blois E, Doeswijk G, Konijnenberg M, Orlandi F . 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2016; 58(2):293-299. DOI: 10.2967/jnumed.116.176636. View

10.

Altai M, Leitao C, Rinne S, Vorobyeva A, Atterby C, Stahl S . Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs. Cells. 2018; 7(10). PMC: 6210767. DOI: 10.3390/cells7100164. View

11.

Millar J, Rozengurt E . Chronic desensitization to bombesin by progressive down-regulation of bombesin receptors in Swiss 3T3 cells. Distinction from acute desensitization. J Biol Chem. 1990; 265(20):12052-8. View

12.

Schroeder R, Muller C, Reneman S, Melis M, Breeman W, de Blois E . A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging. 2010; 37(7):1386-96. PMC: 2886136. DOI: 10.1007/s00259-010-1388-2. View

13.

Stott Reynolds T, Smith C, Lewis M . Peptide-Based Radiopharmaceuticals for Molecular Imaging of Prostate Cancer. Adv Exp Med Biol. 2018; 1096:135-158. DOI: 10.1007/978-3-319-99286-0_8. View

14.

Kurth J, Krause B, Schwarzenbock S, Bergner C, Hakenberg O, Heuschkel M . First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019; 47(1):123-135. DOI: 10.1007/s00259-019-04504-3. View

15.

Wadas T, Wong E, Weisman G, Anderson C . Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010; 110(5):2858-902. PMC: 2874951. DOI: 10.1021/cr900325h. View

16.

Xiao D, Wang J, Hampton L, Weber H . The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter. Gene. 2001; 264(1):95-103. DOI: 10.1016/s0378-1119(00)00596-5. View

17.

Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams Jr C, DiMagno S . Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window. J Nucl Med. 2018; 60(5):656-663. DOI: 10.2967/jnumed.118.221150. View

18.

Zhang J, Niu G, Fan X, Lang L, Hou G, Chen L . PET Using a GRPR Antagonist Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients. J Nucl Med. 2017; 59(6):922-928. PMC: 6004560. DOI: 10.2967/jnumed.117.198929. View

19.

Ananias H, van den Heuvel M, Helfrich W, de Jong I . Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate. 2009; 69(10):1101-8. DOI: 10.1002/pros.20957. View

20.

Altai M, Liu H, Ding H, Mitran B, Edqvist P, Tolmachev V . Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors. J Control Release. 2018; 288:84-95. DOI: 10.1016/j.jconrel.2018.08.040. View